Patients' high acceptability of a future therapeutic HIV vaccine in France: a French paradox?
Acceptability
Acceptance
Confidence
HIV
Therapeutic vaccine
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
09 May 2019
09 May 2019
Historique:
received:
06
01
2018
accepted:
01
05
2019
entrez:
11
5
2019
pubmed:
11
5
2019
medline:
11
7
2019
Statut:
epublish
Résumé
France is the European country with the lowest level of confidence in vaccines. Measurement of patients' acceptability towards a future therapeutic HIV vaccine is critically important. Thus, the aim of this study was to evaluate patients' acceptability of a future therapeutic HIV vaccine in a representative cohort of French patients living with HIV-AIDS (PLWHs). This multicentre study used quantitative and qualitative methods to assess PLWHs' opinions and their potential acceptance of a future therapeutic HIV vaccine. Cross-sectional study on 220 HIV-1 infected outpatients, aged 18-75 years. The participants' characteristics were similar to those of the overall French PLWH population. Responses from the questionnaires showed high indices of acceptance: the mean score for acceptability on the Visual Analog Scale VAS was 8.4 of 10, and 92% of patients agreed to be vaccinated if a therapeutic vaccine became available. Acceptability depended on the expected characteristics of the vaccine, notably the duration of its effectiveness: 44% of participants expected it to be effective for life. This acceptance was not associated with socio-demographic, clinical (mode of contamination, duration of disease), quality of life, or illness-perception parameters. Acceptability was also strongly correlated with confidence in the treating physician. The PLWHs within our cohort had high indices of acceptance to a future therapeutic HIV vaccine. This study was retroactively registered on ClinicalTrials.gov with ID: NCT02077101 in February 21, 2014.
Sections du résumé
BACKGROUND
BACKGROUND
France is the European country with the lowest level of confidence in vaccines. Measurement of patients' acceptability towards a future therapeutic HIV vaccine is critically important. Thus, the aim of this study was to evaluate patients' acceptability of a future therapeutic HIV vaccine in a representative cohort of French patients living with HIV-AIDS (PLWHs).
METHODS
METHODS
This multicentre study used quantitative and qualitative methods to assess PLWHs' opinions and their potential acceptance of a future therapeutic HIV vaccine. Cross-sectional study on 220 HIV-1 infected outpatients, aged 18-75 years.
RESULTS
RESULTS
The participants' characteristics were similar to those of the overall French PLWH population. Responses from the questionnaires showed high indices of acceptance: the mean score for acceptability on the Visual Analog Scale VAS was 8.4 of 10, and 92% of patients agreed to be vaccinated if a therapeutic vaccine became available. Acceptability depended on the expected characteristics of the vaccine, notably the duration of its effectiveness: 44% of participants expected it to be effective for life. This acceptance was not associated with socio-demographic, clinical (mode of contamination, duration of disease), quality of life, or illness-perception parameters. Acceptability was also strongly correlated with confidence in the treating physician.
CONCLUSION
CONCLUSIONS
The PLWHs within our cohort had high indices of acceptance to a future therapeutic HIV vaccine.
TRIAL REGISTRATION
BACKGROUND
This study was retroactively registered on ClinicalTrials.gov with ID: NCT02077101 in February 21, 2014.
Identifiants
pubmed: 31072394
doi: 10.1186/s12879-019-4056-6
pii: 10.1186/s12879-019-4056-6
pmc: PMC6509812
doi:
Substances chimiques
AIDS Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT02077101']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
401Références
AIDS. 2003 Oct 17;17(15):W1-10
pubmed: 14523295
Clin Sci (Lond). 2006 Jan;110(1):59-71
pubmed: 16336205
J Psychosom Res. 2006 Jun;60(6):631-7
pubmed: 16731240
Expert Rev Vaccines. 2009 Feb;8(2):179-90
pubmed: 19196198
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
Vaccine. 2010 Mar 24;28(15):2743-8
pubmed: 20117271
Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):269-81
pubmed: 20545592
AIDS. 2010 Jul 17;24(11):1749-56
pubmed: 20597165
Med Mal Infect. 2010 Dec;40(12):683-90
pubmed: 20822870
Therapie. 2010 Jul-Aug;65(4):357-65, 347-55
pubmed: 20854759
J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):498-505
pubmed: 22205438
J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):506-15
pubmed: 22293550
Hum Vaccin Immunother. 2012 May;8(5):569-81
pubmed: 22634436
Sante Publique. 2012 Nov-Dec;24(6):547-60
pubmed: 23473048
Lancet Infect Dis. 2013 Jul;13(7):606-13
pubmed: 23676442
Immunol Rev. 2013 Jul;254(1):355-71
pubmed: 23772631
Hum Vaccin Immunother. 2013 Aug;9(8):1779-81
pubmed: 23896582
Curr HIV Res. 2013 Sep;11(6):441-9
pubmed: 24033299
Lancet. 2013 Nov 2;382(9903):1525-33
pubmed: 24152939
Euro Surveill. 2013 Oct 31;18(44):null
pubmed: 24176658
Cell. 2014 Feb 13;156(4):633-48
pubmed: 24529371
Vaccine. 2014 Apr 25;32(20):2281-7
pubmed: 24631097
AIDS Care. 2014;26 Suppl 1:S29-40
pubmed: 24731158
Mol Immunol. 2015 Feb;63(2):320-7
pubmed: 25193323
PLoS One. 2014 Nov 05;9(11):e111321
pubmed: 25372044
Vaccine. 2015 Feb 18;33(8):1063-70
pubmed: 25583384
PLoS Curr. 2015 Feb 25;7:null
pubmed: 25789201
EBioMedicine. 2015 Jun 23;2(8):891-7
pubmed: 26425696
J Clin Epidemiol. 2016 Apr;72:116-25
pubmed: 26548542
Expert Rev Vaccines. 2016 Aug;15(8):989-1007
pubmed: 26901118
Expert Rev Vaccines. 2016 Jul;15(7):937-48
pubmed: 27140417
Soc Sci Med. 2016 Jun;159:48-57
pubmed: 27173740
PLoS One. 2016 Jun 03;11(6):e0156118
pubmed: 27257809
EBioMedicine. 2016 Oct;12:295-301
pubmed: 27658738
Curr Opin Virol. 2017 Apr;23:75-81
pubmed: 28453967
JAMA. 2017 Jun 27;317(24):2532-2542
pubmed: 28655021